{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:05:49Z","timestamp":1790935549379,"version":"4.1.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5,31]]},"abstract":"<jats:p>Patients with essential thrombocythemia (ET) and polycythemia vera (PV) have an increased incidence of acute myeloid leukemia and new nonhematologic malignancies compared with the general population. However, information on the factors determining the risk for such complications is limited. In the present study, we investigated whether constitutional genetic variations in DNA repair predispose to leukemic transformation and new nonmyeloid neoplasias in patients with ET and PV. Case-control studies for predisposition to both types of malignancies were nested in a cohort of 422 subjects diagnosed with ET or PV during the period 1973-2010 in several institutions in Spain. A total of 64 incidence cases of leukemia and 50 cases of primary nonmyeloid cancers were accrued. At conditional regression analysis, the Gln\/Gln genotype in the XPD codon 751 showed the strongest association with both leukemic transformation (odds ratio [OR] = 4.9; 95% confidence interval [95% CI], 2.0-12) and development of nonmyeloid malignancies (OR = 4.2; 95% CI, 1.5-12). Additional predictive factors were exposure to cytoreductive agents for leukemic transformation (OR = 3.5; 95% CI, 2.0-6.2) and age for nonmyeloid malignancies (OR = 2.0; 95% CI, 1.4-2.8). These findings provide further evidence about the contribution of inherited genetic variations to the pathogenesis and clinical course of myeloproliferative neoplasms.<\/jats:p>","DOI":"10.1182\/blood-2012-02-411215","type":"journal-article","created":{"date-parts":[[2012,4,12]],"date-time":"2012-04-12T06:36:27Z","timestamp":1334212587000},"page":"5221-5228","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera"],"prefix":"10.1182","volume":"119","author":[{"given":"Juan-Carlos","family":"Hern\u00e1ndez-Boluda","sequence":"first","affiliation":[{"name":"Hematology and Medical Oncology Department, Hospital Cl\u00ednico Universitario, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Pereira","sequence":"additional","affiliation":[{"name":"Hemotherapy and Hemostasis Department, Hospital Cl\u00ednic, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Cervantes","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednic, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Alvarez-Larr\u00e1n","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital del Mar, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Collado","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Department, Hospital Cl\u00ednico Universitario, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Such","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital La Fe, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Jes\u00fas","family":"Arilla","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital de Sagunto, Sagunto, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Boqu\u00e9","sequence":"additional","affiliation":[{"name":"Hematology Department, Institut Catal\u00e0 d'Oncologia, Hospitalet de Llobregat, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Xicoy","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Maffioli","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednic, Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[{"name":"Pathology Department, Hospital del Mar, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Marug\u00e1n","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Department, Hospital Cl\u00ednico Universitario, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Amat","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Department, Hospital Cl\u00ednico Universitario, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Besses","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital del Mar, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicent","family":"Guillem","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology Department, Hospital Cl\u00ednico Universitario, Valencia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111814550547200_B1","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/leu.2008.72","article-title":"Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders.","volume":"22","author":"Cervantes","year":"2008","journal-title":"Leukemia"},{"issue":"2","key":"2019111814550547200_B2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/sj.leu.2404500","article-title":"Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.","volume":"21","author":"Gangat","year":"2007","journal-title":"Leukemia"},{"issue":"7","key":"2019111814550547200_B3","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","article-title":"Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study.","volume":"105","author":"Finazzi","year":"2005","journal-title":"Blood"},{"issue":"11","key":"2019111814550547200_B4","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"2019111814550547200_B5","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"issue":"29","key":"2019111814550547200_B6","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111814550547200_B7","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111814550547200_B8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V91.2.616","article-title":"Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.","volume":"91","author":"Sterkers","year":"1998","journal-title":"Blood"},{"issue":"25","key":"2019111814550547200_B9","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1182\/blood-2011-04-348755","article-title":"Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study.","volume":"118","author":"Frederiksen","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2019111814550547200_B10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2141.2010.08538.x","article-title":"Higher risk of primary cancers after polycythaemia vera and vice versa.","volume":"153","author":"Fallah","year":"2011","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111814550547200_B11","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1158\/1055-9965.EPI-09-0353","article-title":"Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.","volume":"18","author":"Vannucchi","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2019111814550547200_B12","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddl214","article-title":"Molecular bases of progeroid syndromes.","volume":"15","author":"Navarro","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"7147","key":"2019111814550547200_B13","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nature05978","article-title":"Base-excision repair of oxidative DNA damage.","volume":"447","author":"David","year":"2007","journal-title":"Nature"},{"issue":"1","key":"2019111814550547200_B14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/35094000","article-title":"How nucleotide excision repair protects against cancer.","volume":"1","author":"Friedberg","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2019111814550547200_B15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/carcin\/bgi280","article-title":"DNA repair polymorphisms and cancer risk in non-smokers in a cohort study.","volume":"27","author":"Matullo","year":"2006","journal-title":"Carcinogenesis"},{"issue":"13","key":"2019111814550547200_B16","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2004-06-2161","article-title":"Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy.","volume":"104","author":"Allan","year":"2004","journal-title":"Blood"},{"issue":"10","key":"2019111814550547200_B17","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1182\/blood-2002-04-1152","article-title":"The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia.","volume":"100","author":"Seedhouse","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2019111814550547200_B18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1055-9965.EPI-07-2507","article-title":"DNA repair gene XPD polymorphisms and cancer risk: a meta-analysis based on 56 case-control studies.","volume":"17","author":"Wang","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"2019111814550547200_B19","first-page":"1513","article-title":"Polymorphisms in DNA repair genes and associations with cancer risk.","volume":"11","author":"Goode","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"2019111814550547200_B20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"2019111814550547200_B21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"issue":"15","key":"2019111814550547200_B22","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/bioinformatics\/btl268","article-title":"SNPStats: a web tool for the analysis of association studies.","volume":"22","author":"Sol\u00e9","year":"2006","journal-title":"Bioinformatics"},{"issue":"3","key":"2019111814550547200_B23","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","article-title":"Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation.","volume":"138","author":"Gangat","year":"2007","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111814550547200_B24","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/sj.leu.2404977","article-title":"The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus.","volume":"21","author":"Burgstaller","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"2019111814550547200_B25","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1182\/blood-2007-06-095703","article-title":"Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.","volume":"111","author":"Pardanani","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111814550547200_B26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/leu.2009.226","article-title":"The JAK2 46\/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients.","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2019111814550547200_B27","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2008-03-143602","article-title":"Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.","volume":"112","author":"Landgren","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111814550547200_B28","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1055-9965.EPI-11-0659","article-title":"Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.","volume":"20","author":"Bhatia","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4 Pt 2","key":"2019111814550547200_B29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1055\/s-2006-942762","article-title":"Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.","volume":"32","author":"Kiladjian","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"2019111814550547200_B30","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111814550547200_B31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1046\/j.1365-2141.2000.02188.x","article-title":"Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.","volume":"110","author":"Finazzi","year":"2000","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111814550547200_B32","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood.V89.7.2319","article-title":"Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.","volume":"89","author":"Najean","year":"1997","journal-title":"Blood"},{"issue":"11","key":"2019111814550547200_B33","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V95.11.3589","article-title":"Acquired DNA mutations associated with in vivo hydroxyurea exposure.","volume":"95","author":"Hanft","year":"2000","journal-title":"Blood"},{"issue":"6","key":"2019111814550547200_B34","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/blood-2005-08-3429","article-title":"Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders.","volume":"107","author":"Burkitt","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111814550547200_B35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jaad.2003.11.059","article-title":"Hydroxyurea-associated squamous dysplasia.","volume":"51","author":"Sanchez-Palacios","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2019111814550547200_B36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0005-2787(79)90057-1","article-title":"Inhibition of DNA repair in ultraviolet-irradiated human cells by hydroxyurea.","volume":"563","author":"Francis","year":"1979","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"2019111814550547200_B37","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population.","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2019111814550547200_B38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1101\/gad.859501","article-title":"The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases.","volume":"15","author":"Lehmann","year":"2001","journal-title":"Genes Dev"},{"issue":"7","key":"2019111814550547200_B39","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.dnarep.2011.04.028","article-title":"XPB and XPD helicases in TFIIH orchestrate DNA duplex opening and damage verification to coordinate repair with transcription and cell cycle via CAK kinase.","volume":"10","author":"Fuss","year":"2011","journal-title":"DNA Repair (Amst)"},{"issue":"2","key":"2019111814550547200_B40","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/2491","article-title":"Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH.","volume":"20","author":"Coin","year":"1998","journal-title":"Nat Genet"},{"issue":"7","key":"2019111814550547200_B41","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/j.1460-2075.1996.tb00512.x","article-title":"Opening of an RNA polymerase II promoter occurs in two distinct steps and requires the basal transcription factors IIE and IIH.","volume":"15","author":"Holstege","year":"1996","journal-title":"EMBO J"},{"issue":"6","key":"2019111814550547200_B42","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/mutage\/17.6.463","article-title":"ERCC2\/XPD gene polymorphisms and cancer risk.","volume":"17","author":"Benhamou","year":"2002","journal-title":"Mutagenesis"},{"issue":"3","key":"2019111814550547200_B43","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2006-07-037853","article-title":"A common genetic variant in XPD associates with risk of 5q- and 7q-deleted acute myeloid leukemia.","volume":"109","author":"Smith","year":"2007","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/22\/5221\/1492353\/zh802212005221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/22\/5221\/1492353\/zh802212005221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T19:55:30Z","timestamp":1574106930000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/22\/5221\/105475\/A-polymorphism-in-the-XPD-gene-predisposes-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,31]]},"references-count":43,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2012,5,31]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-02-411215","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,31]]}}}